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Background: Meningoencephalitis caused by Escherichia coli is associated with high rates of mortality and risk of
neurological sequelae in newborns and infants and in older or immunocompromised adults. A high prevalence of
neurological disorders has been observed in geriatric populations at risk of hypovitaminosis D.
Methods: In vivo, we studied the effects of vitamin D3 on survival and the host’s immune response in experimental
bacterial meningoencephalitis in mice after intracerebral E. coli infection. To produce different systemic vitamin D3
concentrations, mice received a low, standard, or high dietary vitamin D3 supplementation. Bacterial titers in blood,
spleen, and brain homogenates were determined. Leukocyte infiltration was assessed by histological scores, and
tissue cytokine or chemokine concentrations were measured.
Results: Mice fed a diet with low vitamin D3 concentration died earlier than control animals after intracerebral
infection. Vitamin D deficiency did not inhibit leukocyte recruitment into the subarachnoid space and did not lead
to an increased density of bacteria in blood, spleen, or brain homogenates. The release of proinflammatory interleukin
(IL)-6 was decreased and the release of anti-inflammatory IL-10 was increased in mice fed a diet with high vitamin D3
supplementation.
Conclusion: Our observations suggest a detrimental role of vitamin D deficiency in bacterial central nervous system
infections. Vitamin D may exert immune regulatory functions.
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Death in the acute phase of the disease and neurological
as well as neuropsychological sequelae are frequent com-
plications of bacterial central nervous system (CNS) infec-
tions. Escherichia coli is a Gram-negative bacillus causing
local infections in the urinary tract, abdomen, and lungs.
Systemic spread of these infections is frequent, leading to
sepsis and meningoencephalitis, and is associated with
high rates of mortality and morbidity in newborn infants,
and in immunocompromised or elderly persons despite
advances in antimicrobial chemotherapy [1]. The presence
of the capsule K1 confers invasiveness to the strains and
enables them to penetrate the blood–brain barrier in vivo* Correspondence: mdjukic@gwdg.de
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unless otherwise stated.[2,3]. Several studies in human beings and in the newborn
rat model of hematogenous E. coli meningoencephalitis
suggest that a high degree of bacteremia is required for
meningeal invasion [4,5]. The ability of bacteria to achieve
high bacterial concentrations in blood, increasing the
probability of invasion of the CNS, is greater in im-
munocompromised individuals (for example, neonates)
than in immunocompetent adults, thus explaining the
differences in the occurrence of E. coli K1 meningoenceph-
alitis [6-8]. Invasion of brain microvascular endothelial cells
appears to be a prerequisite for E. coli K1 to induce menin-
goencephalitis [8]. Some E. coli K1 structures, such as outer
membrane protein A (OmpA), Ibe proteins, and cytotoxic
necrotizing factor 1, are necessary for successful bacterial
traversal across the blood–brain barrier [8]. In recent years,
a significant increase in multidrug-resistant E. coli strains
has been observed [9]. In Europe, antimicrobial resistance
in Gram-negative bacteria is spreading, particularly inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Gram-negative isolates in European countries [10]. An-
tibiotics are essential for the control and treatment of E.
coli infections in human beings and animals. However,
it is generally accepted that antimicrobial resistance is
associated with the quantity of antibiotic consumption
[11]. Vaccination may be an important primary preven-
tion strategy in human beings against most E. coli
strains. To date, no effective vaccine is available for the
prevention of these infections [10]. Therefore, the devel-
opment of novel therapeutic strategies for these infec-
tious diseases is of high priority. Vitamin D has long
been known to play a role in building the skeletal sys-
tem and in calcium homeostasis; vitamin D deficiency is
known to be a cause of rickets and osteomalacia and
aggravates osteoporosis [12]. In addition to this well-
known role in mineral and skeletal homeostasis, 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) affects both innate
and adaptive immune responses [13,14]. Cells of the
immune system possess vitamin D receptors and are cap-
able of metabolizing the active form of vitamin D
(1,25(OH)2D3) [15], suggesting vitamin D as an important
factor in the immune response to infection [16]. Studies of
the innate immune response to pathogens such as
Mycobacterium tuberculosis have shown that pathogen-
recognition receptor (PRR)-mediated activation of local-
ized vitamin D metabolism and signaling is a key event as-
sociated with resistance to infection [17]. Epidemiological
studies have established that vitamin D deficiency plays an
important role in susceptibility to tuberculosis [18].
Vitamin D supplementation showed a beneficial modulat-
ing effect on sepsis [19] and on endotoxin shock in mice
[20]. We have previously shown in microglia cultures that
vitamin D3 deficiency may impair the resistance of the
brain against bacterial infections [21]. Taken together,
these data indicate an important role of vitamin D3 in the
clearance of infections and containment of inflammation
by the body’s immune cells. Here we extended our analysis
to the action of vitamin D3 in vivo. The aims of this
study were (i) to investigate the immunomodulatory
capacity of vitamin D and (ii) to examine the impact of
vitamin D3 supplementation as a preventive or adjuvant
therapeutic intervention on the course and mortality of
experimental E. coli meningoencephalitis.
Methods
Vitamin D3 concentration in the blood
To produce different vitamin D3 concentrations in the
circulation, mice were fed with a diet containing either
low (L-VitD; vitamin D3 concentration below the detec-
tion level; normal calcium and phosphate concentrations),
standard (S-VitD; vitamin D3 concentration 1,500 IU/kg
food; normal calcium and phosphate concentrations), or
high (H-VitD; vitamin D3 concentration 75,000 IU/kgfood; normal calcium and phosphate concentrations)
vitamin D3 concentrations (all from ssniff Spezialdiäten
GmbH, Soest, Germany). After 6 weeks, the 25-
hydroxyvitamin D3 serum concentrations were mea-
sured in the mice using liquid chromatography-tandem
mass spectrometry. Serum samples were obtained by
puncture of the retroorbital plexus and measured using
a MassChrom® 25-OH-Vitamin D3/D2 LC-MS/MS kit
(Chromsystems, Munich, Germany). Measurements
were made using an AB Sciex API 4000 LC/MS/MS
system (AB Sciex, Darmstadt, Germany). The HPLC
component was from Shimadzu (Duisburg, Germany).
The assay was adapted to a 50 μl sample volume.
Animals
The animal experiments were approved by the Animal Care
Committee of the University Hospital of Göttingen and by
the Niedersächsische Landesamt für Verbraucherschutz
und Lebensmittelsicherheit, Braunschweig, Lower Saxony,
Germany. C57Bl/6 wild-type mice (2 to 3 months old,
weight 20 to 30 g, Charles River Laboratory) were used in
all experiments [10]. Water and food were available ad
libitum.
Bacteria
The E. coli strain K1 (serotype O18:K1:H7), originally
isolated from the cerebrospinal fluid of a child with neo-
natal meningoencephalitis (and the gift of Dr. Gregor
Zysk, Institute of Medical Microbiology, Düsseldorf,
Germany) was used in all experimental infections. Bacteria
were grown overnight on blood agar plates, harvested in
0.9% saline and stored at −80 °C. Frozen aliquots were
thawed immediately before the experiments and diluted
with saline to the required bacterial concentration.
Induction of meningoencephalitis
For survival experiments, meningoencephalitis was in-
duced by the slow injection of 4,000 colony-forming
units (CFUs) of E. coli K1 in 10 μl sterile saline (0.9%
NaCl) into the right frontal lobe of the cerebral cortex
using a 27-gauge disposable needle [22] under intraperi-
toneal anesthesia with ketamine (100 mg/kg of body
weight) and xylazine (10 mg/kg of body weight). All ani-
mals resumed their normal behavior after awaking from
anesthesia. During the acute disease phase, animals were
weighed and scored every 12 h (0, no apparent behavioral
abnormality; 1, moderate lethargy; 2, severe lethargy; 3,
unable to walk; 4, dead) [19]. Mice with a clinical score of
3 were killed for ethical reasons. In survival experiments,
animals were monitored for 14 days after infection. In
bacteriological studies, using a 27-gauge needle, 10 μl of a
suspension containing 9,000 CFUs of E. coli K1 or an
equal amount of saline were slowly injected into the right
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after infection.
Sample processing
Mice that were killed 20 h after infection were anesthe-
tized with ketamine (100 mg/kg of body weight) and
xylazine (10 mg/kg of body weight). Blood was drawn by
cardiac puncture and 10 μl was used for the determin-
ation of bacterial concentrations. The remaining blood
was stored at 4°C for 30 min and then centrifuged at
3,000 g for 10 min at 4°C. Serum was then transferred to
another tube and stored at −20°C. The whole brain and
spleen were removed. The cerebellum was dissected
from the brain stem. Half of the spleen and the whole
cerebellum were homogenized in 0.9% saline. Bacterial
titers in homogenates and blood were determined by
plating serial 10-fold dilutions in 0.9% saline on sheep
blood agar plates (detection limit: 100 CFU/ml, respect-
ively). The whole cerebrum and the other half of the
spleen were fixed in 4% paraformaldehyde and then em-
bedded in paraffin. In all experiments, a control group
of five mice per group was injected with 0.9% NaCl.
Histological analysis
Paraffin-embedded, 2 μm coronal brain sections from
killed or dead mice from the survival experiments as
well as from animals killed 20 h after infection in the
bacteriological studies were analyzed. Chloroacetate es-
terase staining was performed to evaluate the degree of
inflammation in three superficial meningeal regions and
the hippocampal fissure. This stain is used to detect
neutrophils but it can also stain some monocytes or mac-
rophages [23]. The numbers of chloroacetate-esterase-
stained leukocytes were counted in one high-power field
(×40 objective) per region by a blinded investigator. For
each animal, the leukocyte numbers of the individual
fields were added and then divided by the number of
counted regions.
Flow cytometry
Anesthetized animals were perfused transcardially with
PBS 20 h after infection, and the whole brain was re-
moved and processed. Brain was digested and homoge-
nized with collagenase D (2.5 mg/ml, Roche Diagnostics
GmbH, Mannheim, Germany) and DNase I (2 mg/ml,
Roche Diagnostics GmbH) using a gentleMACS disso-
ciator (Miltenyi Biotec, Germany). The resultant homog-
enates were mechanically dissociated and passed
through a 70-μm nylon cell strainer (BD Biosciences,
Franklin Lakes, NJ, USA). Leukocytes were separated in
a 37/70% Percoll gradient (GE Healthcare, Chalfont St
Giles, Buckinghamshire, UK). Single cells were stained
with the following antibodies: CD45 (30-F11), CD4
(RM4-5), CD27 (LG.3A10), CD11b (M1/70), and Ly6C(HK1.4) purchased from BioLegend (San Diego, CA,
USA), CD3 (145-2C11), CD25 (PC61.5), CD19 (eBio1D3)
NK1.1 (PK136), and FoxP3 (FJK-16 s) provided by
eBioscience (San Diego, CA, USA), and Ly6G (1A8, BD
Pharmigen, Franklin Lakes, NJ, USA) and CCR2
(FAB5538A, R&D Systems, Minneapolis, MN, USA).
At least 50,000 events were acquired on a FACSCanto
II cell analyzer (BD Biosciences) and analyzed using
FlowJo software (version 8.8; Tree Star).
Cytokine and chemokine measurement
Cytokines and chemokines were measured in cerebellum
homogenates of mice killed 20 h after infection and in
the cerebellum and spleen of dead mice from survival
experiments as well as in the cerebellum and spleen ho-
mogenates of five mice per group injected with 0.9% ster-
ile saline. Concentrations of IL-6, IL-10, KC (CXCL1),
IFN-γ, and MIP-2 (CXCL2) were determined using Duo-
Set ELISA development kits (R&D Systems, Wiesbaden,
Germany). Procedures were performed according to the
manufacturer’s instructions. The sensitivity of the assays
for these cytokines and chemokines was 7.5 pg/ml.
Statistics
Vitamin D3 serum concentrations, the weight of ani-
mals, bacterial loads in cerebellum and spleen, and the
mean number of leukocytes per area are shown as mean
and standard deviation (SD) and were analyzed by one-
way-ANOVA and corrected for repeated testing with the
Bonferroni multiple comparisons test. The cytokine and
chemokine concentrations are reported as medians and
corresponding interquartile ranges (Q25 and Q75) and
were analyzed by the Kruskal-Wallis test and corrected
for repeated testing using the Bonferroni method. For
survival analysis, the log-rank test based on a Kaplan-
Meier plot was used. The clinical scores were reported
as box and whiskers (min to max) and were analyzed
using the Kruskal-Wallis test. P values were corrected
for repeated testing with the Bonferroni method. For all
analyses, GraphPad Prism version 5 (GraphPad Software,
San Diego, CA) was used; P ≤ 0.05 was considered statisti-
cally significant.
Results
Vitamin D3 serum concentrations depended on dietary
vitamin D3 content
The analysis of the vitamin D3 metabolite 25-OH-D3 in
serum samples obtained after six weeks of experimental
diet revealed that the vitamin D3 content in the diet de-
termined the vitamin D serum concentrations of the
mice. After 6 weeks of feeding, a diet containing low
vitamin D concentrations (L-VitD) resulted in serum 25-
OH vitamin D3 concentrations significantly lower than
those in S-VitD or H-VitD diet-fed mice (mean ± SD:
Figure 1 Adequate vitamin D3 supply decreases susceptibility
to E. coli meningoencephalitis. (A) Survival, (B) weight loss, and
(C) clinical score of mice fed diets containing different amounts of
vitamin D3 (low (L-VitD), standard (S-VitD) or high (H-VitD) vitamin D
supplementation). Meningoencephalitis was induced by injection of
4,000 CFUs of E. coli K1 into the right frontal lobe of the cerebral
cortex. Kaplan-Meier curves were compared by log-rank test.
Differences in weight loss 24 h after infection are shown as mean
and standard deviation (SD) and were analyzed by one-way-ANOVA
and corrected for repeated testing with the Bonferroni multiple
comparisons test. Clinical scores at 24 h after infection were analyzed
using the Kruskal-Wallis test and corrected for repeated testing by
the Bonferroni method. Data are shown as box and whiskers with
minimum, median and maximum. *P < 0.05.
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Vitamin D3 deficiency led to higher mortality of E. coli
meningoencephalitis
After intracerebral infection with 4,000 CFUs, 15 of 17
vitamin D-deficient mice (L-VitD), 10 of 21 mice fed
a S-VitD diet, and 8 of 15 mice fed a H-VitD diet died
(P = 0.002 L-VitD versus H-VitD, P = 0.003 L-VitD ver-
sus S-VitD, log-rank test, Figure 1A). At 20 hours after
inoculation with 4,000 CFUs of E. coli, all infected ani-
mals were slightly lethargic but able to walk and feed.
At 24 hours after infection, vitamin D-deficient mice
had a tendency towards a greater weight loss (P = 0.22;
Figure 1B), the difference failing to reach statistical sig-
nificance because of high interindividual variation. At
this time, vitamin D-deficient mice (L-VitD) had higher
clinical scores than the two other groups (*P < 0.05;
Kruskal-Wallis test, correction for repeated testing with
the Bonferroni method, Figure 1C). Between animals fed a
S-VitD diet (vitamin D3 concentration 1,500 IU/kg) and
animals fed a H-VitD diet (vitamin D3 concentration
75,000 IU/kg), no statistically significant differences
concerning weight and clinical score were found (P = 0.6,
Kruskal-Wallis test).
Vitamin D3 administration did not influence bacterial
titers in CNS and spleen at the end stage of the disease
or 20 hours after inoculation with E. coli
In 1986, Rook and colleagues [17] found in cultured hu-
man monocytes that active vitamin D [1,25(OH)2D3], can
inhibit the growth of Mycobacterium tuberculosis. There-
fore, we asked whether vitamin D3 plays any antibacterial
role during E. coli infection. The densities of viable bac-
teria in the cerebellum and spleen of animals dying after
an infection with 4,000 CFUs of E. coli were not different
between the three groups (Figure 2A: P = 0.8; Figure 2B:
P = 0.2; one-way ANOVA followed by Bonferroni multiple
comparisons test for repeated testing; mean ± SD).
At 20 hours after infection with 9,000 CFU of E. coli,
the differences of the bacterial titers in the cerebellum
(Figure 2C) and spleen (Figure 2D) of mice of all three
groups were not statistically significant (Figure 2C,
P = 0.2; Figure 2D, P = 0.6; one-way ANOVA followed by
Bonferroni multiple comparisons test for repeated testing).
Bacterial titers in the blood of mice of all three groups
were also not significantly different. Control mice injected
with sterile saline all had sterile cerebellar and spleen
homogenates and blood cultures.
Higher vitamin D3 concentration led to a better clearance
of bacteria in mice that survived the infection
After 14 days of infection all surviving mice (n = 2) fed
a L-VitD diet showed positive bacterial cultures incerebellum homogenates compared with 20% (n = 2/10) of
the animals fed a S-VitD diet (P = 0.09; Fisher’s exact test).
All surviving mice (n = 7) fed a H-VitD diet had negative
bacterial cultures (100%) in cerebellum homogenates
(P = 0.03 compared with vitamin D3-deficient mice and
P = 0.5 compared with mice fed a S-VitD diet; Fisher’s
exact test) indicating that high vitamin D3 concentrations
positively influence the clearance of bacteria in the CNS.
Figure 2 Vitamin D3 pre-treatment did not modulate bacterial loads and did not influence meningeal inflammation during
meningoencephalitis. Bacterial concentrations in (A) the cerebellum and (B) the spleen at the end stage of infection in animals that were
killed or died during the acute phase of infection and (C) in the cerebellum, and (D) the spleen 20 h after intracerebral E. coli K1 infection. (E) The
mean numbers of chloroacetate-esterase-stained leukocytes per area in brain sections of mice fed a diet containing different amounts of vitamin D
(low (L-VitD), standard (S-VitD) or high (H-VitD) vitamin D supplementation), which were killed after 20 h of E. coli meningoencephalitis (n ≥ 15).
Bars indicate mean and standard deviation (SD). Statistical analysis was performed by one-way ANOVA followed by Bonferroni correction for
multiple comparisons. (A,B) n ≥ 8, (C,D,E) n ≥15 mice per group.
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meningeal inflammation or the recruitment of myeloid
cells into the inflamed CNS 20 hours after E. coli infection
Infiltrates by granulocytes and monocytes can already be
observed in the meninges during bacterial meningo-
encephalitis at 12 h after infection with S. pneumoniae
[24]. To investigate the role of vitamin D3 on the men-
ingeal infiltration during E. coli meningoencephalitis, we
quantified the infiltrates in an early stage of the disease
(20 h after infection) by chloroacetate esterase staining.
Histological examination of the brains revealed leukocyte
recruitment into the subarachnoid space 20 hours after E.
coli infection in all groups (n = 17 per group, Figure 2E).
Animals fed a L-VitD diet showed a tendency towards a
higher mean number of leukocytes per area compared to
animals fed a H-VitD diet, but this difference failed to
reach statistical significance (mean ± SD: 41.6 ± 16 versus33.1 ± 21.4; P= 0.4, one-way ANOVA followed by Bonferroni
multiple comparisons test for repeated testing). In addition
to the histological analysis, we analyzed distinct cell types
in the whole brains of mice at 20 h after E. coli infection
by flow cytometry. The relative numbers of the different
cell subtypes among all CD45+ cells found in the CNS are
shown in Table 1. There were no differences between the
groups receiving different amounts of vitamin D3 (P > 0.05).
High vitamin D3 concentrations inhibited the production
of proinflammatory cytokine IL-6 and increased production
of anti-inflammatory cytokine IL-10, while IFN-γ production
in the CNS stayed unaffected
Previous investigations revealed that vitamin D plays im-
portant roles in signaling in both the adaptive and innate
immune response to viral and bacterial infection [16,25].
Vitamin D modulates the production of many cytokines,
Table 1 Subpopulations of T cells in animals fed a diet containing different amounts of vitamin D 20 hours after
infection
Percentage of all CD45+ cellsa
S-VitD L-VitD H-VitD
T cells (CD45+CD3+) 11.25 (4/23.53) 7.5 (1.1/18.50) 10.70 (2.75/23.35)
Regulatory T cells (CD45+CD4+CD3+CD25+FoxP3+) 0.25 (0.04/0.93) 0.05 (0.005/0.17) 0.09 (0.015/0.5)
NK cells (CD45+NK1.1CD3−) 2.25 (1.525/3.43) 3 (0.95/4.4) 1.3 (1.15/1.65)
Inflammatory monocytes (CD45+CD11b+Ly6ChighCCR2+) 28.90 (26.95/34.75) 36.20 (25.9/40.85) 27 (18.10/31.20)
Monocytes (CD45+CD11b+Ly6CintCCR2−) 35.35 (33.3/43.33) 42.20 (31.4/47.3) 34.40 (25.75/37.85)
Granulocytes (CD45+CD11b+Ly6G+CCR2−) 43.25 (28.85/51.58) 26.20 (23/49.95) 34.20 (28.60/54.40)
aData are medians (25th/75th percentiles) determined by forward and side-scatter properties from the whole brain of animals (four or five mice per group) of at
least three separate experiments. Significant differences were not found (P > 0.05; one-way ANOVA followed by Bonferroni correction for multiple comparisons).
L-VitD low vitamin D supplementation; S-VitD, standard vitamin D supplementation; H-VitD, high vitamin D supplementation.
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Macrophage inflammatory protein (MIP-2, CXCL2) is
produced by immune cells resident in the brain and at-
tracts monocytes and neutrophils from the bloodstream
into the cerebrospinal fluid in acute bacterial meningo-
encephalitis [29]. Based on the importance of neutro-
phils and monocytes in controlling bacterial burdens
during early E. coli K1 meningoencephalitis, we mea-
sured IL-6 and IL-10 as key cytokines of the innate
defense system during infection and the chemokines
CXCL1 (KC) and CXCL2 (MIP-2) as key players in the
recruitment of neutrophils into the CNS [30,31]. In-
fected mice showed alterations in the levels of proin-
flammatory mediators. The concentrations of IL-6 in the
cerebellum of animals that died or were killed during
the acute phase of the infection (animals fed a L-Vit D
diet: n = 12; animals fed a S-VitD diet: n = 7; animals fed
a H-VitD diet: n = 8) and of animals killed 20 h after in-
fection (n = 17 for all groups) were significantly de-
creased in mice fed a H-VitD diet compared with
animals fed a L-VitD diet (P < 0.05; Figures 3A, 4A; dif-
ference between L-VitD versus S-VitD not significant).
Animals fed a S-VitD diet also showed a tendency to-
wards higher IL-6 concentrations in the cerebellum than
animals fed a H-VitD diet, but this difference failed to
reach statistical significance (P = 0.2).
In contrast with cerebellar IL-6, IL-10 concentrations
were significantly increased in mice with high vitamin
D3 supplementation that died during the acute phase of
the infection compared with the animals that had received
low or standard vitamin D3 supplementation (*P < 0.05;
Figure 3A). In mice killed 20 h after infection, IL-10 levels
in the cerebellum also tended to be higher in mice with
high vitamin D3 supply, the difference failing to reach
statistical significance (P > 0.05; Figure 4B). The release
of IL-6 and IL-10 in the spleens of animals dying during
the acute phase of infection was similar in all three
groups (P > 0.05; Figure 3B). Cerebellar levels of CXCL1
(KC) were also significantly decreased in animals dyingduring the acute phase of the infection and mice killed
20 h after infection when they had received high vitamin
D3 supplementation, as compared with animals fed a
L-VitD diet (*P < 0.05; Figures 3A, 4C, differences between
L-VitD versus S-VitD not significant). The same effect
was found in the spleens of animals dying during the acute
phase of infection (*P < 0.05; Figure 3B, differences be-
tween L-VitD versus S-VitD not significant).
Although the differences of cerebellar concentrations
of CXCL2 (MIP2) in animals dying during the acute
phase of infection failed to reach statistical significance
(Figure 3A), the highest CXCL2 (MIP 2) concentrations
were found in the cerebellum of animals fed a L-VitD
diet (medians (25th/75th percentiles): 5,237 (1,801/6,287)
pg/ml compared with 2,937 (215.9/5,912) pg/ml in ani-
mals fed a S-VitD diet and 2,859 (402.9/4,294) pg/ml in
animals fed a H-VitD diet; (Figure 3A)). In the spleen,
the concentrations of CXCL2 (MIP2) were significantly
increased in animals dying during the acute phase of in-
fection fed a L-VitD diet compared with animals fed a
H-VitD diet (*P < 0.05; Figure 3B, differences between
L-VitD versus S-VitD not significant). The concentra-
tions of all cytokines and chemokines in the spleen
20 hours after infection (IL-6, IL-10, CXCL1, and
CXCL2) were not different among all three groups stud-
ied. The cytokine and chemokine levels of uninfected
animals (n = 5 per group) and in cerebellum and spleen
homogenates were all lower than the levels in infected
animals. In addition to its influence on bacterial clearance,
IFN-γ has the potential to exacerbate inflammation and
subsequent pathology, primarily through its ability to
modulate the functions of neutrophils and monocytes
or macrophages [32]. Vitamin D is considered to sup-
press the IFN-γ-mediated activation of macrophages. At
20 h after infection, low levels of IFN-γ were found in
the cerebellum homogenates of all three groups, indi-
cating that neither E. coli infection nor the amount of
dietary vitamin D3 substantially influenced the IFN-γ
cerebellar concentrations. The levels of IFN-γ measured in
Figure 3 The protective effect of vitamin D3 correlated with low concentrations of proinflammatory cytokine IL-6 and high concentrations
of anti-inflammatory cytokine IL-10 in cerebellum homogenates of mice dying during the acute phase of infection. Cytokines and
chemokines were measured in (A) cerebellum and (B) spleen homogenates of mice of the survival experiments (time of death or killed because
of severe clinical symptoms after intracerebral E. coli K1 infection (4,000 CFU/mouse): median = 44 h). Each symbol represents the measurement
from an individual mouse (n≥ 7 per group). Horizontal bars indicate median values. Statistical analysis was performed using the Kruskal-Wallis test
and corrected for repeated testing with the Bonferroni method (*P < 0.05, ns: not significant). The time of the tissue collection was not the same
for all animals. Filled circles, standard vitamin D (S-VitD) diet-fed mice (vitamin D3 concentration 1,500 IU/kg food); filled squares, low vitamin D
(L-VitD) diet-fed mice (vitamin D3 concentration less than the detection level); filled triangles, high vitamin D (H-VitD) diet-fed mice (vitamin D3
concentration 75,000 IU/kg food).
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influenced by the amount of dietary vitamin D3 (P = 0.3;
Kruskal-Wallis test). The levels of IFN-γ measured in
cerebellum and spleen homogenates of animals dying dur-
ing the acute phase of infection were all less than the limit
of quantification.Discussion
Here we provide experimental evidence that in bacterial
CNS infection an adequate supply of vitamin D3 de-
creases susceptibility of the brain to E. coli infection
and reduces mortality. Moreover, vitamin D has anti-
inflammatory properties, illustrated in this study by
Figure 4 Pre-treatment with vitamin D3 significantly decreased IL-6 and CXCL 1 in cerebellum homogenates at early infection. (A) IL-6,
(B) IL-10, (C) CXCL 1 (KC), and (D) CXCL 2 (MIP-2) were measured 20 h after intracerebral E. coli K1 infection (9,000 CFU/mouse). Each symbol represents
an individual mouse (n = 17 per group). Horizontal bars indicate median values. Statistical analysis was performed using the Kruskal-Wallis test
and corrected for repeated testing with the Bonferroni method (*P < 0.05, ns: not significant). Filled circles, standard vitamin D (S-VitD) diet-fed
mice (vitamin D3 concentration 1,500 IU/kg food); filled squares, low vitamin D (L-VitD) diet-fed mice (vitamin D3 concentration under detection
level); filled triangles, high vitamin D (H-VitD) diet-fed mice (vitamin D3 concentration 75,000 IU/kg food).
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inflammatory IL-6 concentrations in brain tissue. Clinical
and experimental observations support the hypothesis that
vitamin D has an effect on the immune response to infec-
tion and the ability to eliminate pathogens after entry into
the host. Vitamin D deficiency may therefore be an under-
lying cause of infectious diseases and immune disorders
[14,16,33]. A central feature of many of these non-classical
actions of vitamin D is related to the synthesis of active
1,25(OH)2D in a cell-specific manner: enzyme 25OHD-
1α-hydroxylase (encoded by the gene CYP27B1) is
expressed by many extrarenal tissues, including the im-
mune system [14,34]. For example, activated human T-
and B-cells can convert the inactive intermediate of vita-
min D (also known as 25-hydroxyvitamin D or 25(OH)D)
to active 1,25(OH)2D in vitro [35], and this locally pro-
duced 1,25(OH)2D acts on immune cells in an autocrine
or paracrine fashion [36]. The concentration of the
biologically active form of vitamin D, 1,25(OH)2D, is
dependent on the serum vitamin D (25(OH)D) concentra-
tion, the substrate for CYP27B1 [13,37].
To assess the role of vitamin D in an in-vivo experimen-
tal model of bacterial CNS infection, we analyzed the in-
fluence of the infection on the survival and immune
response of mice fed a diet containing different amounts
of vitamin D3 after injection of E. coli directly into the
right frontal lobe. The mice did not receive antibiotic
treatment; that is, this model tests the ability of mice to
combat pathogens after they have entered the brain andcerebrospinal fluid. The importance of vitamin D for the
resistance to infections has long been appreciated but
poorly understood. This has been especially true for tuber-
culosis. Indeed, prior to the development of specific drugs
for the treatment of tuberculosis, getting out of the city
into sunlight (and fresh air) was the treatment of choice
[16]. In a survey of patients with tuberculosis in London
[38], 56% had undetectable 25(OH)D levels, and an add-
itional 20% had detectable levels below 9 ng/ml (22 nM).
A randomized double-blind intervention study showed
that supplementation with vitamin D may reduce disease
burden in patients with frequent respiratory tract infec-
tions [33]. In-vivo studies in mice and rats also showed
beneficial effects of vitamin D in lipopolysaccharide-
induced sepsis [20,39], and antenatal vitamin D therapy
improved survival in newborn rat pups and enhanced
their lung structure after exposure to endotoxin [40].
The influence of vitamin D on the course of CNS infec-
tions is not known. We therefore asked whether vitamin
D might modulate the course of and survival from infec-
tion after bacterial meningoencephalitis and whether
vitamin D could potentially be used therapeutically to
alleviate CNS pathology. We observed that vitamin D3-
deficient mice died earlier and more frequently than
mice fed a diet containing standard or high amounts of
vitamin D3. The bacterial burdens in mice dying in the
acute phase of infection and mice killed at 20 h were
similar in all three groups, that is, the antibacterial ac-
tion of vitamin D3 in our experimental design was less
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mals with persistent bacteria in the brain compared with
animals with an adequate or high vitamin D3 supply, how-
ever, indicated that vitamin D3 also supported pathogen
elimination in our model. In an early study, Rook and
colleagues [17] demonstrated that active vitamin D,
(1,25(OH)2D), can inhibit the growth of Mycobacterium
tuberculosis in vitro. At this time, the physiological signifi-
cance of this finding was unclear. To clarify the activity of
vitamin D against M. tuberculosis, Liu and colleagues [41]
observed that activation of the toll-like receptor TLR1/2
by a lipoprotein extracted from M. tuberculosis reduced
the viability of intracellular M. tuberculosis in human
monocytes and macrophages, concomitant with an in-
creased expression of the vitamin D receptors and of
CYP27B1 (the enzyme that produces 1,25(OH)2D) in
these cells. Killing of M. tuberculosis occurred only when
the serum in which the cells were cultured contained
adequate levels of 25(OH)D, the substrate for CYP27B1.
Activated vitamin D (1,25(OH)2D) bound to the monocyte
vitamin D receptors and then was able to act as a tran-
scription factor leading to the induction of cathelicidin, a
potent antimicrobial protein [42], and the promotion of
phagocytosis and intracellular killing [41,43,44]. We were
also able to show that, in cultured microglia cells, vitamin
D3 deficiency led to a decreased phagocytosis and
intracellular killing rate of E. coli [21]. One reason for
the mild antimicrobial properties of vitamin D3 in the
present in-vivo model might be that, unlike the human
cathelicidin gene, the mouse gene does not contain a
vitamin D response element, and is not induced directly
by 1,25(OH)2D [16]. Presumably, in addition to cathelici-
din, other immune mediators are involved in the vitamin
D-dependent immune pathways.
In human beings with bacterial meningoencephalitis,
and in animal models of this disease, leukocytes, predom-
inantly myelomonocytic cells such as monocytes, macro-
phages, and neutrophil granulocytes, quickly enter the
subarachnoid space in response to local production of
cytokines, chemokines, and other chemotactic stimuli
[22]. In terms of S. pneumoniae and E. coli, we previously
showed, in vivo, that granulocytes are predominantly in-
volved in the restriction of the multiplication of extracellu-
lar bacteria [24,30]. Different vitamin D3 concentrations
in the present study did not significantly influence the
meningeal invasion with myeloid cells during E. coli
meningoencephalitis; the mean number of chloroacetate-
esterase-stained leukocytes or areas and the recruitment
of myeloid cells into the inflamed CNS 20 hours after E.
coli infection, as assessed by flow cytometry, were compar-
able in all three groups. A study on the immune response
to an allergic stimulus in mice in vivo suggested that vita-
min D supplementation (100 ng 1,25(OH)2D injection)
given after the initial period of sensitization preventedhigh levels of eosinophils associated with a reduced local
inflammatory response in bronchoalveolar lavage fluid
and lung tissue. Constant vitamin D supplementation
(100 ng 1,25(OH)2D injection every other day during the
whole study period), however, did not reduce the entry of
eosinophils into the respiratory epithelia [45]; this is in ac-
cordance with our observation.
One mechanism of how vitamin D3 might act benefi-
cially in infections, could be an increase in pathogen
phagocytosis with adequate levels of vitamin D [21] and
the ability of calcitriol to maintain antimicrobial peptide
gene expression [13,14]. Other mechanisms could be the
regulation of anti- and proinflammatory compounds by
vitamin D. For this purpose, we investigated the pattern
of cytokine and chemokine production, a central feature
in the development of neuroinflammation, neurodegen-
eration, and demyelination in the CNS [46,47]. In bac-
terial meningoencephalitis, after the pathogen crossed
the blood–brain barrier, microglia can respond directly
to intact bacteria or to bacterial cell wall compounds
and produce a wide array of inflammatory mediators, in-
cluding TNF-α, IL-6, IL-12, keratinocyte-derived chemo-
kine (CXCL1/KC), CCL2/MCP-1, CXCL2/MIP-2, and
CCL5/RANTES [48,49]. Neuronal damage in bacterial
meningoencephalitis is caused by the dual effects of an
overwhelming inflammatory response and the direct ac-
tion of bacterial toxins [50,51].
In this study, E. coli led to the production of numerous
cyto- and chemokines in the brain and spleen, including
IL-6, IL-10, CXCL1 and CXCL2 shortly after bacterial
exposure. IL-6 in the cerebellum, CXCL1 in the cerebel-
lum and spleen and CXCL2 in the spleen were clearly
down-regulated in high vitamin D3-fed animals, whereas
the bacterial concentrations were not influenced. Our data
imply that the protective role of vitamin D3 is related to
the reduced release of proinflammatory IL-6 and other
chemokines, such as CXCL1 and CXCL2. Moreover, anti-
inflammatory IL-10 release [52] was significantly increased
in mice dying in the acute phase and fed a diet containing
a high vitamin D3 concentration compared with mice
dying in the acute phase and fed a diet containing low or
standard vitamin D concentrations. This is in accordance
with previously published data that vitamin D can increase
IL-10 production [16,53]. In murine S. pneumoniae men-
ingitis, the absence of IL-10 was associated with higher
proinflammatory cytokine and chemokine concentrations
and more pronounced infiltrates [54]. IL-10 reduced
sepsis-associated hippocampal neuronal damage as a
result of pneumococcal sepsis in mice overexpressing
IL-10 [55]. Also, intravenously administered recombin-
ant IL-10 reduced the level of cerebrospinal fluid pleo-
cytosis, cerebral edema, and intracranial pressure in a
rat model of pneumococcal meningoencephalitis [56].
In our study the IFN-γ levels of animals dying in the
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quantification. In early infection (20 h), low, but ap-
proximately equal IFN-γ levels were measured, sug-
gesting that IFN-γ was not involved in the protective
action of an adequate vitamin D supply.
Conclusions
Our experiments identified for the first time a detrimen-
tal in-vivo effect of vitamin D deficiency on survival in
experimental E. coli meningoencephalitis. A diet con-
taining a standard amount of vitamin D3 (1,500 IU/kg)
is sufficient to decrease the susceptibility of the brain
against CNS infection. A diet containing a high amount
of vitamin D3 (75,000 IU/kg) supported pathogen elim-
ination and can inhibit inflammation in the CNS. Our
results emphasize the necessity of an adequate vitamin
D supply to prevent CNS infection. High-dose vitamin
D may be able to modulate the inflammatory response
to CNS infections. Whether high-dose vitamin D has a
protective effect in combination with antibiotics remains
to be studied.
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